CAG方案治疗成人急性髓系白血病的临床研究

目的观察CAG(阿糖胞苷+阿克拉霉素+粒细胞集落刺激因子)方案诱导治疗急性髓系白血病(AML)的临床疗效。方法以CAG方案作为诱导缓解方案治疗18例AML,18例AML中包括初治12例(其中>70岁7例,<70岁5例),难治4例,复发2例。结果 18例AML患者中8例(44.4%)获完全缓解,3例(16.6%)部分缓解,总有效率61.0%,中位生存期9个月。结论 CAG方案对初发老年AML和原发耐药AML有较高缓解率,并可为部分患者赢得实施异基因造血干细胞移植机会。

Clinical study on CAG regimen in treatment of acute myeloid leukemia.

Objective This study is tried to observe the efficacy of CAG （ aclarubicin, arabinoside and granulocyte colony stimulating factor） regimen in treatment of patients with acute myeloid leukemia （AML） . Methods CAG regimen had been applied in treatment of 18 cases of acute myeloid leukemia including 12 cases of previously untreated patients with AML （7 cases were 〉 70 years old, and 5 cases were 〈 70 years old） ; 4 patients with refractory AML, and 2 patents with relapsed AML. Results The results showed that 8 of 18 cases （44.4%） had achieved complete remission and 3 patients （ 16.6% ） achieved partial remission, and the overall survival rate was 61.0%. Conclusion The treatment for previously untreated elderly patients with AML and primary resistant acute leukemia with modified CAG regimen is effective, thus it can provide opportunity for allo - hematopoietic stem cell transplantion.